Us Bancorp \De\ Gossamer Bio, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 39,655 shares of GOSS stock, worth $42,034. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,655

Previous 39,655 -0.0%

Holding current value

$42,034

Previous $39,000 10.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$0.79 - $1.25 $31,327 - $49,568	39,655 New	39,655 $39,000
Q4 2022 Feb 13, 2023	SELL	$1.74 - $12.87 $180 - $1,338	-104 Reduced 14.75%	601 $1,000
Q3 2022 Oct 27, 2022	BUY	$7.21 - $14.88 $5,083 - $10,490	705 New	705 $8,000
Q1 2022 May 11, 2022	SELL	$8.44 - $12.49 $12,660 - $18,735	-1,500 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$7.25 - $13.23 $1,899 - $3,466	-262 Reduced 14.87%	1,500 $19,000
Q2 2021 Aug 05, 2021	BUY	$8.0 - $9.75 $1,472 - $1,794	184 Added 11.66%	1,762 $14,000
Q1 2021 Apr 28, 2021	SELL	$8.63 - $10.94 $1,881 - $2,384	-218 Reduced 12.14%	1,578 $15,000
Q4 2020 Feb 04, 2021	BUY	$8.3 - $13.59 $7,312 - $11,972	881 Added 96.28%	1,796 $17,000
Q3 2020 Nov 10, 2020	SELL	$11.3 - $14.75 $904 - $1,180	-80 Reduced 8.04%	915 $11,000
Q2 2020 Aug 07, 2020	BUY	$9.52 - $15.98 $2,332 - $3,915	245 Added 32.67%	995 $13,000
Q4 2019 Feb 04, 2020	BUY	$14.82 - $26.79 $7,410 - $13,395	500 Added 200.0%	750 $12,000
Q3 2019 Nov 08, 2019	BUY	$16.02 - $22.47 $4,005 - $5,617	250 New	250 $4,000

Others Institutions Holding GOSS

# of Institutions

112

Shares Held

168M

Call Options Held

450K

Put Options Held

519K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $99.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account